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Spain.Are Comorbidities Associated With
Overall Survival in Patients With Oral
Squamous Cell Carcinoma?
Ursula M. Jariod-Ferrer, MD, PhD,* Jose M. Arbones-Mainar, PhD,y
Marina A. Gavin-Clavero, MD, PhD,z M. Victoria Simon-Sanz, MD, PhD,x
Ignacio Moral-Saez, MD, PhD,k Ana I. Cisneros-Gimeno, MD, PhD,{ and
Javier Martinez-Trufero, MD, PhD#Purpose: Oral squamous cell carcinoma (OSCC) is a highly prevalent type of immunogenic cancer with
a low survival rate in patients with comorbidities owing to toxic habits.
Materials andMethods: A retrospective cohort study was conducted of patients with resectable OSCC
at a tertiary Spanish hospital from 2011 to 2014. The primary predictor variables were comorbidity and
immune biomarkers. Comorbidity was assessed using the Adult Comorbidity Evaluation–27 (ACE-27)
and scored from 1 to 3 (mild to severe decompensation, respectively). The immune biomarkers were
neutrophil-to-lymphocyte ratio (NLR), derived NLR (dNLR), platelet-to-lymphocyte ratio (PLR), and
lymphocyte-to-monocyte ratio (LMR). The primary outcome variable was 5-year overall survival (OS).
Other study variables were stage, margin, and neck management. Receiver operating characteristic curves
were built for each ratio. For the survey of immune biomarkers, area under the curve was computed to
determine cutoff points and investigate their association with OS. Kaplan-Meier estimates of survival
and Cox proportional hazards models were used for longitudinal analysis.
Results: Overall 215 patients were identified (median age, 67 yr; range, 32 to 96 yr; median follow-up,
31 months; range, 7 to 78 months); 159 patients had at least 1 comorbid condition. Results showed that a
severe comorbidity (according to the ACE-27) increased the risk of death by 4 times in patients with OSCC
regardless of stage. NLR, dNLR, LMR, and PLR were associated with OS in the univariate study. Cutoff
points to predict increased mortality were 3, 1.9, 2.6, and 66 for NLR, dNLR, LMR, and PLR, respectively.
Age, comorbidity, stage, margins, and management of the neck were important independent predictors of
decreased OS in OSCC. PLR was marginally associated with OS in the multivariate model.
Conclusion: These results suggest that comorbidity and NLR, dNLR, LMR, and PLR are associated with
5-year OS in patients with resectable OSCC.
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2 COMORBIDITIES AND OVERALL SURVIVAL IN OSCCOral squamous cell carcinoma (OSCC) is the eighth
most common cancer worldwide; despite improved
diagnosis and treatment, 5-year survival remains low,
with an average 5-year survival rate of 50% for all
OSCC locations.1,2 The most common location, with
the worst prognosis, seems to be the tongue,
although this is not confirmed in all studies.3,4 These
poor outcomes are explained by the fact that these
tumors are prone to local invasion and lymph node
metastases. In consequence, patients often develop
locoregional recurrence and second primary
tumors.5,6
Classically, disease stage is the single most power-
ful prognostic variable. Other factors, such as
primary tumor size, lymph node involvement,
distant metastasis, surgical margin, and perineural
invasion, also influence tumor outcomes.7 However,
these parameters are not accurate enough for iden-
tifying patients at the highest risk because other
factors related to the patient, such as comorbidity,
also are involved. Hence, new tools are needed
for the stratification of patients with OSCC. The
association between comorbidity and worse prog-
nosis has been reported and several instruments
have been developed to measure comorbidity.8
The Adult Comorbidity Evaluation–27 (ACE-27) is
one of the most used instruments to measure the
severity of comorbidities in patients with cancer.9
This tool has been extensively validated in OSCC
for predicting survival,9 complications,10 functional
outcome,11 and quality of life.12 Comorbidities
negatively influence the development of OSCC.9
However, in the past few years, a great amount
of scientific evidence has been reported about the
relation between carcinogenesis and inflamma-
tion.13 Tumor cells promote a systemic inflamma-
tory response, which can cause changes in the
counts and ratios of different white blood cell
(WBC) series. These changes have been widely
studied in several types of cancer, and they are
mainly mediated by the liberation of stress-related
substances14 and proinflammatory cytokines, such
as tumor necrosis factor-a. This immune response
can affect the outcome of tumor cells and therefore
can be considered a potential biomarker of tumor
progression and prognosis. In this context, several
ratios derived from peripheral blood, such as the
neutrophil-to-lymphocyte ratio (NLR),15 derived
NLR (dNLR),16 platelet-to-lymphocyte ratio (PLR),17
and lymphocyte-to-monocyte ratio (LMR),18 have
been investigated as useful prognostic indicators
in different cancer subtypes, including OSCC.
The specific aims of the present study were to esti-
mate comorbidity, calculate immune biomarkers, and
investigate their association with patients’ overall
survival (OS).Materials and Methods
To address the research purpose, the authors
designed and implemented a retrospective cohort
study. The study population was composed of all
patients presenting for evaluation and management
of resectable OSCC from January 2011 through
December 2014 at the Miguel Servet University
Hospital (Zaragoza, Spain).
To be included in the study sample, patients 1) had
to be treatment naive with a histopathologic diagnosis
of OSCC; 2) have no history of other cancer in the
head and neck region; 3) have available blood samples
with absolute neutrophil, lymphocyte, monocyte, and
platelets counts; 4) have no hematologic disease or
infection at the time of diagnosis; and 5) have clinical
stages I to IV and be candidates for surgery. Patients
were excluded as study subjects if they had an OSCC
treated with chemotherapy and radiotherapy.
The primary predictor variables investigated were
comorbidity and immune biomarkers. Comorbidities
were assessed using the ACE-2719 and scored from
1 to 3 according to severity (mild, moderate, and
severe, respectively). The ACE-27 includes 27 different
comorbid ailments from different organ systems. Over-
all comorbidity score is assigned according to the high-
est single scoring ailment, except when at least 2 grade
2 ailments are present; in this situation, the score is
designated grade 3. The immune biomarkers were
collected according to the WBC count. The hemato-
logic parameters required were absolute neutrophil
count, absolutemonocyte count, absolute lymphocyte
count, absolute platelet count, and total WBC count.
Immune biomarkers were calculated as ratios:
1) NLR was defined as the absolute neutrophil count
divided by the absolute lymphocyte count; 2) dNLR
was determined as the neutrophil count in relation
to the WBC count subtracted from the neutrophil
count); 3) PLR was defined as the absolute platelet
count divided by the absolute lymphocyte count;
and 4) LMR was established as the absolute lympho-
cyte count divided by the absolute monocyte count.
The primary outcome variable was 5-year OS. Other
variables reviewed were stage, margin, and neck
management.
The stage was classified according to the eighth
edition of the International Union Against Cancer
(UICC)20 and the diagnosis of OSCC was confirmed
pathologically.
Margin status was reported by a dedicated patholo-
gist. According to the method of Batsakis,21 patients
were categorized into 3 groups: clear, close, and
involved margin. Clear margin referred to no evidence
of tumor within 5 mm of the closest point to the surgi-
cal resection margin. Close margin alluded to tumor
within 5 mm of the margin but without evidence of
Table 1. PATIENTSAND TUMOR CHARACTERISTICS AT
TIME OF DIAGNOSIS
Variable All Patients (N = 215)
Gender
Men 145 (67)
Women 70 (33)
Age (yr) 67.5 (58.2; 77.4)
Comorbidity
No or mild comorbidity 125 (58.1)
Moderate to severe
comorbidity
90 (41.9)
Stage
I 98 (45.6)
II 57 (26.5)
III 17 (7.91)
IV 43 (20.0)
Location
Tongue 74 (34.4)
Floor of mouth 41 (19.1)
Buccal mucosa 18 (8.37)
Retromolar trigone and
alveolar ridge
82 (38.1)
Tumor differentiation
Well 61 (28.4)
Moderate 128 (59.5)
Poor 26 (12.1)
Margins
Clear margin ($5 mm) 127 (59.9)
Close (1-4 mm) 57 (26.9)
Positive margins (<1 mm) 28 (13.2)
Management of neck
Elective node dissection 88 (40.9)
Follow-up 81 (37.7)
Therapeutic node dissection 46 (21.4)
Inflammatory biomarkers
JARIOD-FERRER ET AL 3tumor at the margin. Involved margin meant evidence
of frank tumor at the margin.
Patients underwent surgical options for neck
management (elective or therapeutic neck dissection)
or watchful waiting with physical and radiologic
follow-up. Elective treatment of the neck in patients
with early-stage clinically N0 has been historically
controversial.5 Ipsilateral elective neck dissection
was performed for stage II. Therapeutic neck dissec-
tion was carried out for patients with diagnosed nodal
metastasis. Watchful waiting with physical and radio-
logic follow-up was adopted for patients with OSCC
stage I,.
The c2 or Mann-Whitney U test was used to
compare categorical or continuous variables, respec-
tively. Receiver operating characteristic (ROC) curves
were built for each immunologic ratio to ascertain its
sensitivity and specificity for the prediction of vital
status (alive or dead) at the end of follow-up. Areas
under ROC curves (AUC-ROCs) were computed with
the trapezoidal rule, and the Youden index
(sensitivity + specificity  1) was used to determine
optimal cutoff points.
The Kaplan-Meier estimator was used to calculate
5-year OS (main outcome of the study) and its modula-
tion by comorbidity and immune biomarkers (predic-
tors). Survival differences were compared with the
log-rank test. A prognostic multivariate model was
built using Cox regression analysis. Data were
analyzed using R 3.1.3 (http://www.r-project.org).
Level of significance was set at .05.
The Clinical Research Ethics Committee of Aragon
approved this study. The Declaration of Helsinki was
followed in the present study.NLR 2.22 (1.68; 3.29)
dNLR 1.54 (1.21; 2.06)
PLR 104 (78.0; 146)
LMR 3.17 (2.40; 4.20)
Note: Data are presented as median (first quartile; third quar-
tile) or number (percentage).
Abbreviations: dNLR, derived neutrophil-to-lymphocyte
ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-
to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
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PATIENT CHARACTERISTICS
A total of 215 patients who received surgery under
general anesthesia for OSCC were included in this
analysis. Patient and tumor characteristics are listed
in Table 1. Table 2 presents the study variables
segmented by comorbidity groups. The median age
of patients at the time of diagnosis was 67.5 years
(range, 32 to 95 yr) and most patients were men
(67.4%; male-to-female ratio, 2:1). Data retrieved
from these patients’ clinical records showed that 159
patients (73.9%) presented an associated comorbidity.
Forty percent of men and 30% of women were
smokers (P < .001). Eighty-two men (58%) and 8
women (12%) drank alcohol everyday (P < .001).
According to the ACE-27 score, those comorbidities
were classified as mild (32.1%), moderate (27%), or
severe (15%). The total follow-up was 5 years (median,
41 months; range, 7 to 78 months).The most common primary tumor location was the
tongue (34.4%), followed by the floor of the mouth
(19.9%), and most such tumors were moderately
differentiated. Based on the eighth edition of the
TNM-UICC and American Joint Committee on Cancer
staging system,20 155 patients (72%) had early disease
(stage I or II), whereas 60 (28%) had locally advanced
disease (stage III or IV). Negativemarginswere present
in 127 patients (59.9%) and close and positive margins
were observed in 57 and 28 patients, respectively
Table 2. PATIENT AND TUMOR CHARACTERISTICS BY COMORBIDITIES
No or Mild Comorbidity
(n = 125)
Moderate to Severe
Comorbidity (n = 90) P Value
Gender .408
Men 81 (64.8) 64 (71.1)
Women 44 (35.2) 26 (28.9)
Age (yr) 65.3 (55.3; 74.0) 71.6 (62.6; 81.7) <.001
Stage .742
I 60 (48.0) 38 (42.2)
II 33 (26.4) 24 (26.7)
III 10 (8.00) 7 (7.78)
IV 22 (17.6) 21 (23.3)
Location .873
Tongue 44 (35.2) 30 (33.3)
Floor of mouth 23 (18.4) 18 (20.0)
Buccal mucosa 9 (7.20) 9 (10.0)
Retromolar trigone and
alveolar ridge
49 (39.2) 33 (36.7)
Tumor differentiation .532
Well 34 (27.2) 27 (30.0)
Moderate 78 (62.4) 50 (55.6)
Poor 13 (10.4) 13 (14.4)
Margins .619
Clear margin ($5 mm) 76 (61.3) 51 (58.0)
Close (1-4 mm) 34 (27.4) 23 (26.1)
Positive margins (<1 mm) 14 (11.3) 14 (15.9)
Management of neck .676
Elective node dissection 53 (42.4) 35 (38.9)
Follow-up 44 (35.2) 37 (41.1)
Therapeutic node dissection 28 (22.4) 18 (20.0)
Inflammatory biomarkers
NLR 2.05 (1.61; 2.96) 2.51 (1.80; 3.71) .012
dNLR 1.44 (1.13; 1.94) 1.71 (1.37; 2.38) .006
PLR 98.3 (72.2; 130) 108 (81.9; 148) .028
LMR 3.40 (2.67; 4.29) 2.85 (2.12; 3.80) .007
Note:Data are presented as median (first quartile; third quartile) or number (percentage). P values indicate statistical difference.
Abbreviations: dNLR, derived neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
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4 COMORBIDITIES AND OVERALL SURVIVAL IN OSCC(26.9 and 13.2%). A larger percentage (62.3%) of
patients underwent elective or therapeutic neck
surgery and then watchful follow-up with physical
and radiologic examinations. Median values for NLR,
dNLR, PLR, and LMR were 2.22, 1.54, 104, and 3.17,
respectively.ROC CURVES AND CUTOFF POINTS FOR IMMUNE
BIOMARKERS
Figure 1 shows ROC curves plotting the sensitivity
and specificity for different cutoff points of immune
biomarkers. The AUC-ROCs were 64.4, 61.4, 77.3,
and 56.2% for the prediction of OS based on the
presurgical evaluation of NLR, dNLR, LMR, and PLR,
respectively. Next, specificity and sensitivity werebalanced to calculate the optimal threshold values to
predict OS. Those cutoff points were 3, 1.9, 2.6, and
66 for NLR, dNLR, LMR, and PLR, respectively.SURVIVAL ANALYSIS
During 5 years of follow-up (median, 31 months;
range, 7 to 78 months), the 1-, 3-, and 5-year OSs for
the cohort were 88, 68, and 57%, respectively. Death
from any cause was observed in 74 patients (34%);
43 died of cancer-specific causes (20%) and 30 died
of intercurrent disease (14%). During this period,
141 patients (66%) presented recurrences, with local
recurrence being the most frequent (13%). Adjuvant
therapy was administered to 49 patients (23%): 28
patients (13%) were treated with radiotherapy after
FIGURE1. A, Receiver operating characteristic curve for neutrophil-to-lymphocyte ratio. B, Receiver operating characteristic curve for derived
neutrophil-to-lymphocyte ratio. C, Receiver operating characteristic curve for platelet-to-lymphocyte ratio. D, Receiver operating characteristic
curve for lymphocyte-to-monocyte ratio. A-D, AUCs with confidence intervals and optimal cutoff points according to the Youden index are dis-
played. AUC, area under the receiver operating characteristic curve.
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JARIOD-FERRER ET AL 5the surgery and 21 (10%) were treated with chemo-
therapy plus radiotherapy.
Comorbidity had a relevant effect on survival
because patients showed considerably worse survival
with increasing ACE-27 score (Fig 2). Next, cutoff
points were calculated to stratify patients and then
Kaplan-Meier analysis was performed (Fig 3). NLR,
dNLR, LMR, and PLR were associated with OS
(P # .001, P = .001, P # .001, and P = .0079 by log-
rank test, respectively; Fig 3A-D). Table 3 presents
the strength of the association between the study
variables and 5-year OS.
Age, comorbidity, stage, margins, management of
the neck, and immune biomarkers were evaluated in
a multivariate Cox regression model. This analysisshowed that age, moderate and severe comorbidity,
tumor stage, margins, and management of the neck
were relevant independent predictors of decreased
OS (Table 4). PLR ($66) also was marginally associated
with an approximately 4-fold increase of all-cause mor-
tality (P = .059)Discussion
In the present study, comorbidity was the clinical
parameter most meaningfully related to OS. The prog-
nostic capacity of comorbidity at the time of diagnosis
depended mainly on the different comorbid organ sys-
tem ailments classified as moderate or severe comor-
bidity. Likewise, some immune biomarkers were
FIGURE2. Survival curves according to the ACE27 in the 3-category severity system (mild, moderate, and severe) for the number of patients at
risk at the beginning of the study versus the number alive at the end of the study. ACE27, Adult Comorbidity Evaluation–27.
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6 COMORBIDITIES AND OVERALL SURVIVAL IN OSCCrelated to OS in bivariate analyses. However, only PLR
was marginally associated with death in the multivar-
iate analysis when all predictor variables were simulta-
neously taken into account.
Previous studies have shown a noteworthy associa-
tion between decreased OS and comorbidity in head
and neck squamous cell carcinoma and OSCC.9,22
The present study showed a relevant relation
between OS and comorbidity only in patients with
moderate and severe comorbidity. The present
patients presented increased comorbidities
compared with those in other studies, reflecting the
health-related problems of this cohort. However,
despite this increased prevalence of overall comorbid-
ity, 42% of patients had moderate or severe comorbid-
ity at the time of diagnosis. This percentage was
somewhat larger than that reported by Piccirillo and
Costas,23 although a similar prevalence of comorbidity
was reported by Ankola et al22 who studied patients
with head and neck cancer using the ACE-27 index
and by Singh et al24 in patientswith head and neck can-
cer graded by the Kaplan-Feinstein comorbidity index.Therefore, the present data confirm that almost half
the patients with OSCC present serious health prob-
lems that compromise survival independently of can-
cer stage at the moment of diagnosis. The present
study is the first to collect information on resectable
OSCC-associated comorbidity in Spain.
It is widely accepted that cancer is related to inflam-
mation and OSCC is one of the most immunogenic
tumors, as reported by Ock et al.25 Tsai et al26 showed
that pretreatment circulating monocyte count was an
independent prognostic factor for survival in oral can-
cer. The present study showed that the NLR, dNLR,
PLR, and LMR in the peripheral blood of patients
with OSCC at the time of diagnosis and before surgical
treatment were strongly associated with OS in the uni-
variate study. Proctor et al27 found that the NLR and
dNLR had similar prognostic value. However, in the
present study, dNLR had a slightly decreased prog-
nostic value because it presented a smaller AUC-ROC
for the prediction of OS. In line with these results, Ras-
souli et al17 reported that a higher pretreatment NLR
(>4.27) was associated with higher rates of recurrence
FIGURE 3. A, Survival curves for NLR according to the cutoff point calculated in the sample (Fig 1A). B, Survival curves for dNLR according to
the cutoff point calculated in the sample (Fig 1B). C, Survival curves for dNLR according to the cutoff point calculated in the sample (Fig 1C).
D, Survival curves for LMR according to the cutoff point calculated in the sample (Fig 1D).A-D,Curves shows the number of patients at risk at the
beginning of the study versus the number alive at the end of follow-up. dNLR, derived neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-
monocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
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JARIOD-FERRER ET AL 7(35 vs 7%; P < .0001) and that a higher pretreatment
PLR was associated with decreased survival.
In the multivariate analysis, NLR, dNLR, and LMR
were not associatedwith OS, aswere age, comorbidity,
stage, margin status, andmanagement of the neck. The
reason for only PLR appearing to be close to a prog-
nostic factor in the multivariate analysis is not clear.
The authors hypothesize that although lymphocytes
are key components of host immunity,28 platelet count
might have better prognostic characteristics related to
inflammation. In line with this hypothesis, high
platelet count also has been reported as a powerful
prognostic indicator in solid tumors.29 Also, it could
be connected to the capacity of creating a thrombus,which involves tumoral cells, and migration outside
the blood vessels generating a new tumoral bed.
The most relevant result of this study is the confir-
mation of the strong prognostic value of comorbidity
in a homogeneous cohort of patients affected by
OSCC treated by surgery first. The results showed
that a severe comorbidity increased the risk of death
by 4 times in this cohort. The second important result
is the suggestive finding of the prognostic role of im-
mune ratios (NLR, dNLR, PLR, LMR) in OSCC, which
allowed an approximate portrait of the immune
response landscape created by the tumor presence.
Differences in statistical relevance between studies
probably occur from the heterogeneity of patients in
Table 3. UNIVARIATE ANALYSIS USING KAPLAN-
MEIER ESTIMATOR COMPARED WITH LOG-RANK TEST
FOR PROBABILITY OF 5-YEAR OVERALL SURVIVAL
Events at
Beginning
of Study, n
Events
(Death)
at End
of Study, n
P Value by
Log-Rank
Test
Age (>80 yr) 177 48 <.001
Comorbidity .003
No comorbidities 69 13
Mild 58 18
Moderate 56 28
Severe 32 14
Stage <.001
I 98 16
II 57 16
III or IV 60 41
Margins <.001
Clear 127 33
Close 57 21
Involved 28 17
Management of neck <.001
Elective neck
dissection
88 19
Therapeutic neck
dissection
46 35
Follow-up 81 19
Immune biomarkers
NLR >3 61 36 <.001
dNLR >1.9 66 31 .0.1
PLR >66 170 61 .007
LMR <2.6 146 37 <.001
Abbreviations: dNLR, derived neutrophil-to-lymphocyte
ratio; LMR, lymphocyte-to-monocyte ratio; NLR, neutrophil-
to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
Jariod-Ferrer et al. Comorbidities and Overall Survival in OSCC.
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Table 4. MULTIVARIATE ANALYSIS USING COX
PROPORTIONAL HAZARDS MODEL OF PROGNOSTIC
FACTORS FOR OVERALL SURVIVAL
HR 95% CI P Value
Age (>80 yr) 3.84 1.94-7.59 .001
Comorbidity
No comorbidities 1
Mild 1.94 0.79-4.79 .148
Moderate 2.36 1.04-5.40 .041
Severe 4.04 1.56-10.49 .004
Stage
I 1
II 2.10 0.88-5.00 .095
III or IV 2.90 1.00-8.41 .050
Management of neck
Elective neck dissection 1
Follow-up 1.15 0.47-2.79 .763
Therapeutic neck
dissection
2.95 1.29-6.72 .010
Margins
Negative 1
Close or positive 1.91 1.07-3.41 .028
Immune biomarkers
NLR >3 1.21 0.40-3.63 .735
dNLR >1.9 0.845 0.31-2.31 .743
PLR >66 4.06 0.95-17.42 .059
LMR <2.6 1.04 0.54-2.00 .905
Abbreviations: CI, confidence interval; dNLR, derived
neutrophil-to-lymphocyte ratio; HR, hazard ratio; LMR,
lymphocyte-to-monocyte ratio; NLR, neutrophil-to-
lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.
Jariod-Ferrer et al. Comorbidities and Overall Survival in OSCC.
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8 COMORBIDITIES AND OVERALL SURVIVAL IN OSCCterms of ethnicity, tumor site and stage, and
geographic differences. Therefore, prospective and
multicentric studies are needed to find the accurate
relation between systemic immune biomarkers and
the outcome of patients with OSCC.
A limitation of the present work is the small sample
of patients with OSCC, which warrants further valida-
tion in a larger cohort. Intratumoral cell populations
were not identified as predictors of survival to focus
in clinical prognostic factors. A subsequent study is
needed to link intratumoral cell populations, pretreat-
ment WBC count, and OS. The strength of this study is
its longitudinal analysis, which decreases statistical
type I error compared with single cross-sectional
analyses and supports a cause-and-effect relation.
Thus, based on these results, the authors strongly
believe that immune ratios and comorbidity should
be measured in patients diagnosed with OSCC and
should be considered at the time of staging the patientwith OSCC. Further studies are warranted to test
whether these inexpensive new biomarkers might
assist the more classic prognostic factors to maximize
their predictive value.
According to the present results, the authors sug-
gest that comorbidity and NLR, dNLR, PLR, and LMR
are associated with 5-year OS in patients with resect-
able OSCC. These results indicate that severe comor-
bidity in patients with resectable OSCC increases the
risk of death by 4 times independently of stage.
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